NASDAQ:ONCS OncoSec Medical (ONCS) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free ONCS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.20▼$0.9452-Week Range N/AVolume52.49 million shsAverage Volume2.22 million shsMarket Capitalization$1.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get OncoSec Medical alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About OncoSec Medical Stock (NASDAQ:ONCS)OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.Read More Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. ONCS Stock News HeadlinesJune 24, 2023 | finance.yahoo.comONCS - OncoSec Medical IncorporatedJune 23, 2023 | markets.businessinsider.comWhy Is OncoSec Medical (ONCS) Stock Up 100% Today?June 15, 2023 | msn.comWhy John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJune 15, 2023 | msn.comWhy Is OncoSec Medical (ONCS) Stock Down 48% Today?May 18, 2023 | finance.yahoo.comOncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 16, 2023 | msn.comOncoSec Medical plunges 35% lower on sale of 1.4M shares of common stockMay 16, 2023 | finance.yahoo.comOncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMay 16, 2023 | finance.yahoo.comOncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical programApril 27, 2023 | finance.yahoo.comOncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL ProgramApril 11, 2023 | finance.yahoo.comOncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 10, 2023 | msn.comWhy OncoSec Medical Shares Are Soaring TodayApril 10, 2023 | finance.yahoo.comOncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesApril 6, 2023 | benzinga.comOncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket TradingApril 3, 2023 | finance.yahoo.comOncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting StudyApril 3, 2023 | msn.comOncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trialApril 3, 2023 | finance.yahoo.comOncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 TreatmentMarch 1, 2023 | marketwatch.comOncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%March 1, 2023 | msn.comWhy is OncoSec Medical (ONCS) Stock Up 91% Today?January 16, 2023 | reuters.comONCS.OQ - | Stock Price & Latest News | ReutersJanuary 5, 2023 | benzinga.comOncoSec Medical Stock (NASDAQ:ONCS), Quotes and News SummaryDecember 8, 2022 | msn.comPeering Into OncoSec Medical's Recent Short InterestDecember 5, 2022 | finance.yahoo.comOncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022November 30, 2022 | marketwatch.comOncoSec Shares Drop 25% on Equity Offer Pricing After 51% Tuesday SurgeNovember 30, 2022 | finance.yahoo.comOncoSec Announces Pricing of $3.5 Million Public OfferingNovember 24, 2022 | finance.yahoo.comOncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin CancerSee More Headlines Receive ONCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/14/2021Today5/19/2024Fiscal Year End7/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ONCS CUSIPN/A CIK1444307 Webwww.oncosec.com Phone(855) 662-6732Fax858-430-3832Employees40Year Founded2011Profitability EPS (Most Recent Fiscal Year)($15.2865) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-868.29% Return on Assets-160.61% Debt Debt-to-Equity RatioN/A Current Ratio0.89 Quick Ratio0.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / BookN/AMiscellaneous Outstanding Shares4,550,000Free Float4,494,000Market Cap$1.26 million OptionableNot Optionable Beta1.99 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesRobert H. ArchPresident, CEO & Non-Independent DirectorGeorge ChiChief Financial OfficerDavid CantonVice President-Research & DevelopmentSandra AungChief Clinical Development Officer & Senior VPBridget O'KeeffeVice President-Clinical DevelopmentKey Competitors9 Meters BiopharmaNASDAQ:NMTRPolarityTENASDAQ:PTEIQEiger BioPharmaceuticalsNASDAQ:EIGRSintx TechnologiesNASDAQ:SINTGRI BioNASDAQ:GRIView All Competitors ONCS Stock Analysis - Frequently Asked Questions How were OncoSec Medical's earnings last quarter? OncoSec Medical Incorporated (NASDAQ:ONCS) released its earnings results on Tuesday, December, 14th. The biotechnology company reported ($5.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($8.14) by $2.64. When did OncoSec Medical's stock split? Shares of OncoSec Medical reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Punit Dhillon's approval rating as OncoSec Medical's CEO? 2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of OncoSec Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN). This page (NASDAQ:ONCS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OncoSec Medical Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.